Jaguar Health, INC Form 4 insider transactions

Jaguar Health's Director, John Micek, was granted 7,377 shares of common stock and 7,377 stock options, following two significant reverse stock splits in 2024 and 2025.

Jaguar Health's Chief of Sustainable Supply, Steven R. King, received grants of 11,740 restricted stock units and 11,740 stock options.

Jaguar Health's CEO and President, Lisa A. Conte, was granted 28,592 restricted stock units and 28,592 stock options on December 11, 2025, under the company's 2014 Stock Incentive Plan.

Jaguar Health, Inc. granted its Chief of Staff, Chief Compliance Officer, and General Counsel, Jonathan S. Wolin, 11,740 restricted stock units and 11,740 stock options.

Jaguar Health's CSO acquired 11,740 shares and options on December 11, 2025.

Jaguar Health, Inc. director James J. Bochnowski was granted restricted stock units and stock options on December 11, 2025, aligning his interests with shareholders.

Jaguar Health, Inc. Director Jonathan B. Siegel was granted 7,377 restricted stock units and options to purchase 7,377 shares of common stock on December 11, 2025.

Jaguar Health, Inc. Director Anula Jayasuriya was granted 5,870 restricted stock units and 5,870 stock options on December 11, 2025, as reported in a Form 4 filing.

Jaguar Health's Chief Financial Officer, Carol R. Lizak, was granted 11,740 restricted stock units and 11,740 stock options on December 11, 2025.

A director of Jaguar Health, Jonathan B. Siegel, exchanged a maturing convertible promissory note for a new note with an extended maturity and received warrants as an inducement.

Jaguar Health, Inc. Director John Micek exchanged an expiring convertible promissory note for a new one with a later maturity and received warrants as an inducement in an issuer exchange offer.

Jaguar Health, Inc. Director James J. Bochnowski exchanged a maturing convertible promissory note for a new note with a later maturity date and received a warrant to purchase additional common stock as an inducement.

Steven R. King, an officer of Jaguar Health, Inc., exchanged an expiring convertible promissory note for a new note with a later maturity date and received a warrant to purchase common stock as an inducement.

Jaguar Health, Inc.'s Chief Scientific Officer, Pravin R Chaturvedi, participated in an issuer exchange offer, swapping an expiring convertible promissory note for a new one with a later maturity and receiving warrants as an inducement.

Jaguar Health, Inc. Chief of Staff Jonathan S. Wolin exchanged a maturing convertible promissory note for a new note with a later maturity date and received warrants as an inducement.

Jaguar Health, Inc.'s CEO and President, Lisa A. Conte, exchanged an existing convertible promissory note for a new one with an extended maturity and received a warrant to purchase additional common stock as an inducement.

Steven R. King, Chief of Sustainable Supply, Ethnobotanical Research and Intellectual Property and Secretary at Jaguar Health, Inc., reports a transaction involving restricted stock units converting into common stock.

Lisa Conte, CEO of Jaguar Health, reports the acquisition of common stock through the vesting of restricted stock units.

Director John Micek acquired a convertible promissory note and warrants for Jaguar Health common stock on March 31, 2025.

Steven R. King, a Jaguar Health executive, acquired a convertible promissory note and warrants to purchase common stock, according to a recent SEC filing.

Director Jonathan B. Siegel acquired a convertible promissory note and warrants in Jaguar Health, Inc.

Lisa A. Conte, CEO of Jaguar Health, acquired a convertible promissory note and warrants to purchase common stock, according to a Form 4 filing.

Jonathan S. Wolin, Chief of Staff, Chief Compliance Officer, and General Counsel of Jaguar Health, Inc., acquired a convertible promissory note and warrants to purchase common stock.

Pravin R Chaturvedi, Chief Scientific Officer of Jaguar Health, acquired a convertible promissory note and warrants to purchase common stock, according to a Form 4 filing.

James J. Bochnowski, a director of Jaguar Health, acquired a convertible promissory note and warrants to purchase common stock, according to a recent SEC filing.

Carol R. Lizak, CFO of Jaguar Health, acquired a convertible promissory note and warrants to purchase common stock, according to a Form 4 filing.

Carol R. Lizak, CFO of Jaguar Health, reports the acquisition of restricted stock units and stock options, as well as adjustments due to a reverse stock split.

Pravin R. Chaturvedi, Chief Scientific Officer of Jaguar Health, Inc., reports the acquisition of stock options and restricted stock units.

Jonathan S. Wolin, Chief of Staff, Chief Compliance Officer, and General Counsel of Jaguar Health, Inc., reports acquisition of common stock and stock options.

Lisa Conte, CEO of Jaguar Health, reports acquiring stock options and restricted stock units on October 8, 2024, under the company's 2014 Stock Incentive Plan.